Preclinical Biopharmaceuticals
Our research programs have as main objectives colon cancer and metabolic syndrome.
Main Technology
Different patents of phytochemical compounds and their most active molecules, which demonstrate a high antioxidant capacity, a promising antiproliferative capacity and inhibitory activity against cancer cells.
What have we discovered
New sources of obtaining phytochemical compounds with outstanding anticancer molecules that have demonstrated proven efficacy after repeated preclinical tests, both with “in vitro” cell cultures, and in “in vivo” laboratory tests.
Cellbitec is currently in the patent phase of several of these phytochemical compounds and their extraction methodology.
Cellbitec has several research projects funded through programs of the European Union and the Ministry of Science, Innovation and Universities of the Government of Spain, where evaluation screening and development of new phytochemicals in different genera and plant species are developed.
PHASES OF STUDY OF A MEDICINAL PRODUCT
DISCOVERY
PATENT
STRUCTURAL ELUCIDATION
ISOLATION
PURIFICATION
TAXONOMY
PRECLINIC
TOXICITY
PHARMACKINETICS
FORMULATION
STABILITY
BIOLOGICAL RESEARCH
FASE I
DOSAGE
SUPPLY
TOXICITY
PHARMACKINETICS
SECURITY
FASE II
EFFECTIVENESS
SECURITY
THERAPEUTIC INDICATION
FASE III
COMPARISON WITH STANDARD TREATMENTS
BETWEEN 2 AND 4 YEARS
BETWEEN 3 AND 7 YEARS
Our Results
Biopharmaceutical
E01EL
Therapeutic area
Oncology
Objective Disease
Colon cancer
Research Fase
Preclinic: In vitro
100%
Preclinic: In vivo
100%
Clinic I
5%
Clinic II
No initiated
Clinic III
No initiated
Biopharmaceutical
B02EP
Therapeutic area
Oncology
Objective Disease
Colon cancer
Research Fase
Preclinic: In vitro
100%
Preclinic: In vivo
100%
Clinic I
No initiated
Clinica II
No initiated
Clinica III
No initiated
Biopharmaceutical
T03CL
Therapeutic area
Oncology
Objective Disease
Colon cancer
Research Fase
Preclinic: In vitro
100%
Preclinic: In vivo
No initiated
Clinic I
No initiated
Clinic II
No initiated
Clinic III
No initiated
Biopharmaceutical
Z04ZLL
Therapeutic area
Oncology
Objective Disease
Colon cancer
Research Fase
Preclinic: In vitro
100%
Preclinic: In vivo
No initiated
Clinic I
No initiated
Clinic II
No initiated
Clinic III
No initiated
Our R&D Projects
Nano-nutraceuticals with antitumor activity against colon cancer
Project focused on obtaining functional extracts, derived from solanaceae, cucurbits and legumes, which can be used, individually or in combination, for the preparation of nutraceuticals with application in the prevention and / or treatment of colon cancer.
Participating Entities
Project funded by the 2017 RETOS Collaboration Program, with EU ERDF funds managed by the Ministry of Science, Innovation and Universities of the Government of Spain.
Resolution granted according to expedient RTC-2017-6540-1.
Brassiceuticals
Project focused on the identification and isolation of bioactive components present in different plants of the brassica genus, and the evaluation of their nutraceutical capacity in the prevention of both different types of cancer and metabolic syndrome.
Collaborating Entity
Project funded by the Torres Quevedo Doctors State Program 2018 for the Promotion of Talent and its Employability in R&D, managed by the Ministry of Science, Innovation and Universities of the Government of Spain.
Resolution granted according to expedient RTC-2017-6540-1.
Discover the Future
We are a biotechnological and pharmaceutical company with a strong sense of responsibility about medicine, nutraucetic and efficient bioactive principles discovery with natural origin in the plant biology area.